Emerging roles of noncoding RNAs in multiple myeloma: A review

Yang, Qian; Shen, Xianjuan; Su, Zhangyao; Ju, Shaoqing

doi:10.1002/jcp.27547

Cited by 12 publications

(5 citation statements)

References 144 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies indicate that long non-coding RNAs (lncRNAs) play an important role in the pathophysiology of MM [54]. Recent studies have shown that prostate cancer-associated ncRNA transcript 1 (PCAT-1) plays an important role in the pathophysiology of MM and has a regulatory role in p38, where it induces an increase that correlates with proliferation and chemoresistance [55]. Therefore, regulating PCAT-1 could be an important therapeutic target in the context of regulating p38 in MM.…”

Section: Non-coding Rnas In the Regulation Of P38mentioning

confidence: 99%

p38 MAPK Molecular Targeting for Next-Generation Multiple Myeloma Therapy

Morales-Martinez,

Vega

2024

Preprint

View full text Add to dashboard Cite

Resistance to therapy and disease progression are the main causes of mortality in most cancers. In particular, the development of resistance is an important limitation affecting the efficacy of therapeutic alternatives for cancer, including chemotherapy, radiotherapy, and immunotherapy. Signaling pathways are largely responsible for the mechanisms of resistance to cancer treatment and progression, and multiple myeloma is no exception. p38 mitogen-activated protein kinase (p38) is downstream of several signaling pathways specific to treatment resistance and progression. Therefore, in recent years, developing therapeutic alternatives directed at p38 MAPK has been of great interest, in order to reverse chemotherapy resistance and prevent progression. In this review, we discuss recent findings on the role of p38, including recent advances in our understanding of its expression and activity as well as its isoforms, and its possible clinical role based on the mechanisms of resistance and progression in multiple myeloma.

show abstract

Section: Non-coding Rnas In the Regulation Of P38mentioning

confidence: 99%

p38 MAPK Molecular Targeting for Next-Generation Multiple Myeloma Therapy

Morales-Martinez,

Vega

2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Studies indicate that long non-coding RNAs (lncRNAs) play an important role in the pathophysiology of MM [53]. Recent studies have shown that prostate cancer-associated ncRNA transcript 1 (PCAT-1) plays an important role in the pathophysiology of MM and has a regulatory role in p38, where it induces an increase that correlates with proliferation and chemoresistance [54]. Therefore, regulating PCAT-1 could be an important therapeutic target in the context of regulating p38 in MM.…”

Section: P38 Regulation 221 Transcription Factors In the Regulation O...mentioning

confidence: 99%

p38 Molecular Targeting for Next-Generation Multiple Myeloma Therapy

Morales-Martínez,

Vega

2024

Cancers

View full text Add to dashboard Cite

Resistance to therapy and disease progression are the main causes of mortality in most cancers. In particular, the development of resistance is an important limitation affecting the efficacy of therapeutic alternatives for cancer, including chemotherapy, radiotherapy, and immunotherapy. Signaling pathways are largely responsible for the mechanisms of resistance to cancer treatment and progression, and multiple myeloma is no exception. p38 mitogen-activated protein kinase (p38) is downstream of several signaling pathways specific to treatment resistance and progression. Therefore, in recent years, developing therapeutic alternatives directed at p38 has been of great interest, in order to reverse chemotherapy resistance and prevent progression. In this review, we discuss recent findings on the role of p38, including recent advances in our understanding of its expression and activity as well as its isoforms, and its possible clinical role based on the mechanisms of resistance and progression in multiple myeloma.

show abstract

“…130,131 Other Cancers Multiple myeloma (MM) is a malignant proliferative disease of plasma cells and is usually confined to the bone marrow. 132 Sun et al 133 found that the lncRNA MALAT1 is upregulated in MM and is negatively associated with miR-181a-5p. Moreover, this group demonstrated that in the context of MALAT1 interference, the proliferative and adhesive abilities of myeloma cells were inhibited, whereas apoptosis was promoted; miR-181a-5p overexpression exhibited similar effects on myeloma cells.…”

Section: Urogenital Cancersmentioning

confidence: 99%

Advances in Understanding the LncRNA-Mediated Regulation of the Hippo Pathway in Cancer

Wang

Feng

et al. 2021

OTT

View full text Add to dashboard Cite

Long noncoding RNAs (lncRNAs) are a class of RNA molecules that are longer than 200 nucleotides and cannot encode proteins. Over the past decade, lncRNAs have been defined as regulatory elements of multiple biological processes, and their aberrant expression contributes to the development and progression of various malignancies. Recent studies have shown that lncRNAs are involved in key cancer-related signaling pathways, including the Hippo signaling pathway, which plays a prominent role in controlling organ size and tissue homeostasis by regulating cell proliferation, apoptosis, and differentiation. However, dysregulation of this pathway is associated with pathological conditions, especially cancer. Accumulating evidence has revealed that lncRNAs can modulate the Hippo signaling pathway in cancer. In this review, we elaborate on the role of the Hippo signaling pathway and the advances in the understanding of its lncRNA-mediated regulation in cancer. This review provides additional insight into carcinogenesis and will be of great clinical value for developing novel early detection and treatment strategies for this deadly disease.

show abstract

Emerging roles of noncoding RNAs in multiple myeloma: A review

Cited by 12 publications

References 144 publications

p38 MAPK Molecular Targeting for Next-Generation Multiple Myeloma Therapy

p38 MAPK Molecular Targeting for Next-Generation Multiple Myeloma Therapy

p38 Molecular Targeting for Next-Generation Multiple Myeloma Therapy

Advances in Understanding the LncRNA-Mediated Regulation of the Hippo Pathway in Cancer

Contact Info

Product

Resources

About